Bleeding risk and safety profile related to the use of eptifibatide: A current review

Expert Opinion on Drug Safety

Volumn 11, Issue 2, 2012, Pages 315-324

  Saab, Fadi ^a   Ionescu, Costin ^a   Schweiger, Marc J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Clinical efficacy; Eptifibatide; Glycoproteins IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; COLLAGEN; EPTIFIBATIDE; FIBRONECTIN; HEPARIN; HIRULOG; PLACEBO; TENECTEPLASE; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL DECISION MAKING; CONTINUOUS INFUSION; CORONARY STENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EARLY INTERVENTION; ERYTHROCYTE TRANSFUSION; GLANZMANN DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAOCULAR HEMORRHAGE; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK BENEFIT ANALYSIS; STRUCTURE ACTIVITY RELATION; THERAPY DELAY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOGENESIS; UNSTABLE ANGINA PECTORIS;

ANIMALS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; RISK FACTORS;

EID: 84857423112     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.650164     Document Type: Review

References (60)

1. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase i: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76(1):142-54 (Pubitemid 17093202)
2. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329(10):673-82
3. Rao SV, O'Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47(4):809-16 (Pubitemid 43243106)
4. The Esprit Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356(9247):2037-44
5. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (GRACE). Eur Heart J 2003;24(20):1815-23 (Pubitemid 37280247)
6. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92(8):930-5 (Pubitemid 37214804)
7. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-63 (Pubitemid 37430344)
8. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286(6):708-13 (Pubitemid 33010364)
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689-96
10. Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol 2009;53(22):2019-27
11. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76(1):101-8 (Pubitemid 15240423)
12. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353(9148):227-31 (Pubitemid 29088046)
13. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979;64(5):1393-401
14. Mustard JF, Packham MA, Kinlough-Rathbone RL, et al. Fibrinogen and ADP-induced platelet aggregation. Blood 1978;52(2):453-66
15. Phillips DR, Agin PP. Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced twodimensional gel electrophoresis. J Biol Chem 1977;252(6):2121-6 (Pubitemid 8077399)
16. Kohmura C, Gold HK, Yasuda T, et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb J Vasc Biol Am Heart Assoc 1993;13(12):1837-42 (Pubitemid 23360571)
17. Scarborough RM. Development of eptifibatide. Am Heart J 1999;138(6 Pt 1):1093-104
18. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat rev Drug Discov 2010;9(10):804-20
19. Qin J, Vinogradova O, Plow EF. Integrin bidirectional signaling: a molecular view. PLoS Biol 2004;2(6):e169
20. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2(9):703-16 (Pubitemid 37361786)
21. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000;275(29):21785-8 (Pubitemid 30621742)
22. D'Souza SE, Haas TA, Piotrowicz RS, et al. Ligand and cation binding are dual functions of a discrete segment of the integrin beta 3 subunit: cation displacement is involved in ligand binding. Cell 1994;79(4):659-67 (Pubitemid 24363809)
23. Scarborough RM, Rose JW, Hsu MA, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J biol chem 1991;266(15):9359-62 (Pubitemid 21906663)
24. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96(5):1488-94 (Pubitemid 27375341)
25. The Impact II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349(9063):1422-8
26. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95(4):846-54 (Pubitemid 27091524)
27. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76(17):1222-7
28. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91(8):2151-7
29. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94(9):2083-9 (Pubitemid 26360497)
30. Bell DN, Spain S, Goldsmith HL. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res 1990;58(1):47-60 (Pubitemid 20146923)
31. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation 2001;104(4):406-11 (Pubitemid 32678269)
32. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287(5):618-21 (Pubitemid 34252014)
33. Winchester DE, Wen X, Brearley WD, et al. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol 2011;57(10):1190-9
34. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: receptor suppression using integrilin therapy. N Engl J Med 1998;339(7):436-43
35. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360(21):2176-90
36. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30 (Pubitemid 351724451)
37. Gibson CM, Kirtane AJ, Murphy SA, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006;152(4):668-75 (Pubitemid 44419381)
38. Le May MR, Wells GA, Glover CA, et al. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST). Circ Cardiovasc interv 2009;2(4):330-8
39. Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39(3):377-86 (Pubitemid 34117492)
40. Giugliano RP, Roe MT, Harrington RA, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 2003;41(8):1251-60 (Pubitemid 36438983)
41. Carere RG, Webb JG, Buller CE, et al. Suture closure of femoral arterial puncture sites after coronary angioplasty followed by same-day discharge. Am Heart J 2000;139(1 Pt 1):52-8 (Pubitemid 30043624)
42. Kiemeneij F, Laarman GJ, Odekerken D, et al. A randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches: the access study. J Am Coll Cardiol 1997;29(6):1269-75 (Pubitemid 27201945)
43. Koch KT, Piek JJ, Prins MH, et al. Triage of patients for short term observation after elective coronary angioplasty. Heart 2000;83(5):557-63 (Pubitemid 30316723)
44. Ziakas AA, Klinke BP, Mildenberger CR, et al. Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study. Am Heart J 2003;146(4):699-704 (Pubitemid 37281717)
45. Fung AY, Saw J, Starovoytov A, et al. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009;53(10):837-45
46. Fischell TA, Attia T, Rane S, et al. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18(10):487-91 (Pubitemid 44497339)
47. Deibele AJ, Jennings LK, Tcheng JE, et al. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary eptifibatide (ICE) trial. Circulation2010;121(6):784-91
48. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95(4):809-13 (Pubitemid 27091518)
49. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32(2):311-19 (Pubitemid 28396477)
50. Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97(3):426-9 (Pubitemid 43133064)
51. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-6 (Pubitemid 38625397)
52. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129(11):886-90 (Pubitemid 28549817)
53. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998;54(9-10):701-6 (Pubitemid 29024201)
54. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100(6):2071-6 (Pubitemid 35001239)
55. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104(8):870-5 (Pubitemid 32778035)
56. Memon MA, Blankenship JC, Wood GC, et al. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000;109(3):213-17
57. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355(21):2203-16 (Pubitemid 44791162)
58. Anderson JL, Adams CD, Antman EM, et al. ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;133:e426-e579
59. Tcheng JE, Lim IH, Srinivasan S, et al. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circ Cardiovasc Interv 2009;2(1):43-51
60. Marso SP, Amin AP, House JA, et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 2010;303(21):2156-64